Enimmune corporation
TWO: 6564.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhe Wei Zhang
- Employees
- 27
- Headquarters
- Taichung City, Taiwan
- IPO year
- 2018
- Market cap
- NT$1.4B
- Website
- https://www.enimmune.com.tw
Loading 6564…
Loading profile data…Frequently asked questions about 6564
What does Enimmune corporation (6564.TWO) do?
Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan. Its products include Tuberculin PPD RT23 SSI, an approved drug for tuberculin test to determine whether the patient is infected with tuberculosis. The company is also involved in the development of vaccines to prevent various infectiou...
Where does 6564.TWO trade?
Enimmune corporation (6564.TWO) trades on the Taipei Exchange.
What sector is 6564.TWO in?
Enimmune corporation (6564.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Enimmune corporation?
Zhe Wei Zhang is the chief executive officer of Enimmune corporation (6564.TWO).
Where is Enimmune corporation headquartered?
Enimmune corporation is headquartered in Taiwan.
Does 6564.TWO pay a dividend?
Enimmune corporation (6564.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6564.TWO go public?
Enimmune corporation (6564.TWO) completed its initial public offering in 2018.